Vertex Pharmaceuticals (WBO:VRTX) PE Ratio: 29.00 (As of Jun. 24, 2026) — Near Median


WBO:VRTX Vertex Pharmaceuticals Inc WBO:VRTX
90 GF Score
Price €420.05
GF Value €439.78
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals PE Ratio?

Vertex Pharmaceuticals WBO:VRTX +2.43% 90 PE Ratio is 29.00 as of Jun. 24, 2026, which is 7% above its 10-year median of 27.22. GuruFocus rates WBO:VRTX with a GF Score™ of 90/100 and a GF Value™ of €439.78 (Fairly Valued). The stock has 4 warning signs investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-06-24), Vertex Pharmaceuticals's share price is €420.05. Vertex Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €14.49. Therefore, Vertex Pharmaceuticals's PE Ratio for today is 29.00.

Good Sign:

Vertex Pharmaceuticals Inc stock PE Ratio (=27.78) is close to 3-year low of 25.14.

During the past 13 years, Vertex Pharmaceuticals's highest PE Ratio was 198.85. The lowest was 17.89. And the median was 27.22.

Vertex Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2026 was €3.48. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €14.49.

As of today (2026-06-24), Vertex Pharmaceuticals's share price is €420.05. Vertex Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was €16.17. Therefore, Vertex Pharmaceuticals's PE Ratio without NRI ratio for today is 25.97.

During the past 13 years, Vertex Pharmaceuticals's highest PE Ratio without NRI was 2361.38. The lowest was 14.72. And the median was 33.49.

Vertex Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2026 was €3.87. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was €16.17.

During the past 3 years, the average EPS without NRI Growth Rate was 7.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was -19.00% per year.

During the past 13 years, Vertex Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 84.40% per year. The lowest was -96.70% per year. And the median was -1.25% per year.

Vertex Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2026 was €3.51. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €14.61.

Back to Basics: PE Ratio


Vertex Pharmaceuticals  (WBO:VRTX) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Vertex Pharmaceuticals PE Ratio Related Terms


Vertex Pharmaceuticals PE Ratio Historical Data

* Premium members only.

The historical data trend for Vertex Pharmaceuticals's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals PE Ratio Chart

Vertex Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.37 22.53 29.29 At Loss 29.59

Vertex Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss 31.82 27.62 29.59 26.49

WBO:VRTX vs REGN, ALNY, RVMD: PE Ratio Comparison

For the Biotechnology subindustry, Vertex Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's PE Ratio falls into.


WBO:VRTX
90GF Score
Vertex Pharmaceuticals Inc WBO:VRTX
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vertex Pharmaceuticals PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Vertex Pharmaceuticals's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=420.05/14.485
=29

Vertex Pharmaceuticals's Share Price of today is €420.05.
Vertex Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €14.49.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 29.00 mean?
Vertex Pharmaceuticals (WBO:VRTX) has a PE Ratio of 29.00 as of Jun. 24, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Vertex Pharmaceuticals and its competitors. This is near median its historical median of 27.22. Over the past decade, Vertex Pharmaceuticals' PE Ratio has ranged from 17.89 to 198.85.
Is Vertex Pharmaceuticals' PE Ratio too high?
Vertex Pharmaceuticals' current PE Ratio of 29.00 is near median its 10-year median of 27.22. Over the past 10 years, this metric has ranged from a low of 17.89 to a high of 198.85. Overall, Vertex Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' PE Ratio compare to REGN and ALNY?
Vertex Pharmaceuticals' PE Ratio of 29.00 can be compared against companies in the Biotechnology industry. Historically, Vertex Pharmaceuticals' own PE Ratio has ranged from 17.89 to 198.85 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Biotechnology company?
A good PE Ratio depends on the Biotechnology industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current PE Ratio is 29.00, which is near median its own 10-year median of 27.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (WBO:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is €439.78, compared to a current price of €420.05 — trading 4.5% below its estimated fair value. The current PE Ratio is 29.00, which is near median its 10-year median of 27.22. Vertex Pharmaceuticals' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For Vertex Pharmaceuticals (WBO:VRTX), the current PE Ratio is 29.00 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vertex Pharmaceuticals (WBO:VRTX) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued. The current stock price of €420.05 is trading 4.5% below its estimated GF Value™ of €439.78. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for WBO:VRTX:

  • PE Ratio: 29.00 (near median its 10-year median of 27.22)
  • GF Value™: €439.78 vs. price of €420.05 (4.5% below fair value)
  • GF Score™: 90/100 with 4 warning signs

No single metric tells the full story. See the WBO:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
90GF Score

Get the complete analysis for WBO:VRTX

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€420.05
Price
€439.78
GF Value